These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10097884)

  • 21. Protecting the health of patients at cardiovascular and cerebrovascular risk - Boehringer-Ingelheim's South African journey: from fibrinolytics (Actilyse and Metalyse) to the protective anti-hypertensive (Micardis).
    Cardiovasc J Afr; 2009; 20(1):81-2. PubMed ID: 19287823
    [No Abstract]   [Full Text] [Related]  

  • 22. Does effect of a neuroprotective agent on volume of experimental animal cerebral infarct predict effect of the agent on clinical outcome in human stroke?
    Jonas S; Tran AQ; Eisenberg E; Azam M; Viera D; Grumet S
    Ann N Y Acad Sci; 1997 Oct; 825():281-7. PubMed ID: 9369994
    [No Abstract]   [Full Text] [Related]  

  • 23. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis.
    Smith RW; Scott PA; Grant RJ; Chudnofsky CR; Frederiksen SM
    Acad Emerg Med; 1999 Jun; 6(6):618-25. PubMed ID: 10386679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model.
    Jørgensen HS; Nakayama H; Kammersgaard LP; Raaschou HO; Olsen TS
    BMJ; 1999 Jul; 319(7205):288-9. PubMed ID: 10426737
    [No Abstract]   [Full Text] [Related]  

  • 25. Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke.
    Heiss WD; Grond M; Thiel A; von Stockhausen HM; Rudolf J; Ghaemi M; Löttgen J; Stenzel C; Pawlik G
    J Cereb Blood Flow Metab; 1998 Dec; 18(12):1298-307. PubMed ID: 9850142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolytic therapy.
    Goldhaber SZ
    Adv Intern Med; 1999; 44():311-25. PubMed ID: 9929714
    [No Abstract]   [Full Text] [Related]  

  • 27. Hyperacute stroke therapy with tissue plasminogen activator.
    Alberts MJ
    Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model.
    Vanderschueren S; Van Vlaenderen I; Collen D
    Stroke; 1997 Sep; 28(9):1783-8. PubMed ID: 9303026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute neurovascular syndromes: hurry up, please, it's time.
    Kennedy J; Buchan AM
    Stroke; 2004 Feb; 35(2):360-2. PubMed ID: 14757879
    [No Abstract]   [Full Text] [Related]  

  • 30. Stroke and t-PA--Triggering New Paradigms of Care.
    Snow SJ
    N Engl J Med; 2016 Mar; 374(9):809-11. PubMed ID: 26962901
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department.
    ; Brown MD; Burton JH; Nazarian DJ; Promes SB
    Ann Emerg Med; 2015 Sep; 66(3):322-333.e31. PubMed ID: 26304253
    [No Abstract]   [Full Text] [Related]  

  • 32. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Walsh M; Fromm G
    Ann Emerg Med; 2006 Mar; 47(3):297. PubMed ID: 16492504
    [No Abstract]   [Full Text] [Related]  

  • 34. Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy.
    Carandang RA
    JAMA Neurol; 2016 Mar; 73(3):265-7. PubMed ID: 26810152
    [No Abstract]   [Full Text] [Related]  

  • 35. Canadian guidelines for intravenous thrombolytic treatment in acute stroke. A consensus statement of the Canadian Stroke Consortium.
    Norris JW; Buchan A; Cote R; Hachinski V; Phillips SJ; Shuaib A; Silver F; Simard D; Teal P
    Can J Neurol Sci; 1998 Aug; 25(3):257-9. PubMed ID: 9706731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Facilitating emergency use of alteplase for stroke.
    Stump LS; Alfano SL
    Am J Health Syst Pharm; 1997 Jun; 54(12):1447-9. PubMed ID: 9194991
    [No Abstract]   [Full Text] [Related]  

  • 37. Cerebrovascular and carotid artery disease.
    August M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Sep; 92(3):253-6. PubMed ID: 11552139
    [No Abstract]   [Full Text] [Related]  

  • 38. Intra-arterial rtPA treatment of stroke assessed by diffusion- and perfusion-weighted MRI.
    Lansberg MG; Tong DC; Norbash AM; Yenari MA; Moseley ME
    Stroke; 1999 Mar; 30(3):678-80. PubMed ID: 10066870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In reply.
    Edlow JA; Smith EE
    Ann Emerg Med; 2013 Oct; 62(4):433. PubMed ID: 24054100
    [No Abstract]   [Full Text] [Related]  

  • 40. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Mann J
    Ann Emerg Med; 2006 Oct; 48(4):476; author reply 477. PubMed ID: 16997689
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.